Upregulated Transcription Factor PITX1 Predicts Poor Prognosis in Kidney Renal Clear Cell Carcinoma-Based Bioinformatic Analysis and Experimental Verification

Table 1

A baseline data for KIRC patients on TCGA.

Clinical characteristics	Overall (n%)
Age	539
≤60	269 (49.9%)
>60	270 (50.1%)
Gender	539
Female	186 (34.5%)
Male	353 (65.5%)
Race	532
Asian	8 (1.5%)
Black or African American	57 (10.7%)
White	467 (87.8%)
Laterality	538
Left	252 (46.8%)
Right	286 (53.2%)
T stage	539
T1	278 (51.6%)
T2	71 (13.2%)
T3	179 (33.2%)
T4	11 (2%)
N stage	257
N0	241 (93.8%)
N1	16 (6.2%)
M stage	506
M0	428 (84.6%)
M1	78 (15.4%)
Pathologic stage	536
Stage I	272 (50.7%)
Stage II	59 (11%)
Stage III	123 (22.9%)
Stage IV	82 (15.3%)
Histologic grade	531
G1	14 (2.6%)
G2	235 (44.3%)
G3	207 (39%)
G4	75 (14.1%)
Primary therapy outcome	147
PD	11 (7.5%)
SD	6 (4.1%)
PR	2 (1.4%)
CR	128 (87.1%)
OS event	539
Alive	366 (67.9%)
Dead	173 (32.1%)
DSS event	528
Alive	420 (79.5%)
Dead	108 (20.5%)
PFI event	539
Alive	378 (70.1%)
Dead	161 (29.9%)

TCGA: The Cancer Genome Atlas; KIRC: kidney renal clear cell carcinoma; PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response; OS: overall survival; DSS: disease-specific survival; PFI: progress-free interval.